Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended): An immunogenic composition comprising IPV, a bacterial polysaccharide or oligosaccharide and a ~~stabilising~~ stabilizing agent, all formulated as a dried composition, which after reconstitution, is capable of generating an immune response against polio virus.

2. (Currently amended): The immunogenic composition of claim 1 comprising a capsular polysaccharide or oligosaccharide antigen from *Haemophilus influenzae* b ~~(Hib)~~.

3. (Currently amended): The immunogenic composition of claim 1 ~~or 2~~ wherein the polysaccharide or oligosaccharide is conjugated to a carrier protein.

4. (Previously presented): The immunogenic composition of claim 3 wherein the polysaccharide or oligosaccharide is conjugated to tetanus toxoid.

5. (Currently amended): The immunogenic composition of claim 2~~[-4]~~ wherein the polysaccharide or oligosaccharide is adsorbed onto aluminium phosphate.

6. (Currently amended): The immunogenic composition of claim 1~~-5~~ comprising a capsular polysaccharide or oligosaccharide derived from *N. meningitidis* C.

7. (Currently amended): The immunogenic composition of claim 1~~-6~~ additionally comprising a capsular polysaccharide or oligosaccharide derived from any of *N. meningitides* A, Y or W or combination thereof.

8. (Currently amended): The immunogenic composition of claim 6~~-7~~ wherein the meningococcal polysaccharides or oligosaccharides are conjugated to a carrier protein.

9. (Currently amended): The immunogenic composition of claim 8 comprising a ~~Hib~~ *Haemophilus influenzae* b polysaccharide or oligosaccharide and at least one meningococcal polysaccharide or oligosaccharide conjugated to the same type of carrier protein.

10. (Currently amended): The immunogenic composition of claim 8 comprising a ~~Hib~~ *Haemophilus influenzae* b polysaccharide or oligosaccharide and at least one meningococcal polysaccharide or oligosaccharide conjugated to different carrier proteins.

11. (Currently amended): The immunogenic composition of claim 1~~-11~~ wherein the dried composition is freeze dried.

12. (Currently amended): The immunogenic composition of claim 1~~-11~~ wherein the dried composition is freeze dried.

13. (Currently amended): The immunogenic composition of claim 1~~-12~~ wherein the dried composition is a foamed glass.

14. (Currently amended): The immunogenic composition of claims 1~~-11~~ wherein the dried composition is a highly viscous liquid.

15. (Previously presented): The immunogenic composition of claim 14 wherein the highly viscous liquid has not been frozen.

16. (Currently amended): A method of making a vaccine comprising the step of reconstituting the immunogenic composition of claims 1-15 in an aqueous solution.

17. (Currently amended): The method of claim 16 wherein the aqueous solution comprises acellular or whole cell Diphtheria toxoid, Tetanus toxoid and Pertussis antigens ~~(acellular or whole cell)~~.

18. (Previously presented): The method of claim 17 where the DTP vaccine is at least in part adjuvanted with aluminium hydroxide.

19. (Currently amended): The method of claim 17 wherein the aqueous solution comprises Hepatitis B surface antigen.

20. (Currently amended): A kit comprising the immunogenic composition of claims 1~~–15~~ in one container and liquid acellular or whole cell DTP ~~(acellular or whole cell)~~ vaccine in a second container.

21. (Previously presented): The kit of claim 20 further comprising Hepatitis B surface antigen in the second container.

22. (Currently amended): A vaccine comprising the immunogenic compositions of claims 1~~–15~~.

23. (Previously presented): The vaccine of claim 22 which is reconstituted into an aqueous solution prior to use.

24. (Currently amended): A container with a water repellent internal surface containing the vaccine of claim 22~~–23~~.

25. (Currently amended): A method of preserving a composition comprising IPV, a bacterial polysaccharide or oligosaccharide and a ~~stabilising~~ stabilizing agent comprising the steps of:

a) preparing a preservation sample by suspending or dissolving IPV and a bacterial polysaccharide or oligosaccharide in a solution of a ~~stabilising~~ stabilizing agent;

b) subjecting the preservation sample to such temperature and pressure conditions that solvent is lost from the preservation sample; and

c) removing solvent until the preservation sample dries to form a solid or highly viscous liquid in which the antigenicity of IPV is retained.

26. (Previously presented): The method of claim 25 wherein the preservation sample is dried in a container with a water repellent interior surface.

27. (Currently amended): The method of claim 25 ~~or 26~~ wherein the preservation sample bubbles to form a foam during step b).

28. (Previously presented): The method of claim 27, wherein the sample is at least partially frozen before commencing the drying process.

29. (Previously presented): The method of claim 27 wherein the preservation sample becomes at least partially frozen during step b).

30. (Currently amended): The method of claim 25 wherein, during step b) the preservation sample is subjected to such temperature and pressure conditions so that the preservation sample ~~looses~~ loses solvent by evaporation, without freezing or bubbling involved in foam formation, to form a viscous liquid and during step c) solvent is removed until the preservation sample dries to form a highly viscous liquid.

31. (Currently amended): The method of claim 26~~-30~~ wherein the preservation sample comprises ~~Hib~~ *Haemophilus influenzae* b polysaccharide or oligosaccharide.

32. (Currently amended): The method of claim 26~~-31~~ wherein the preservation sample comprises polysaccharide or oligosaccharide derived from any of *N. meningitides* A, C, Y or W or combination thereof.